Merck, Incyte immunotherapy combination effective in lung cancer study – Reuters
Business Wire |
Merck, Incyte immunotherapy combination effective in lung cancer study
Reuters A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, … Incyte shares lifted by positive early-stage trial results for cancer drug Aduro drug to be tested with Keytruda in second indication |
